(Q44397391)

reason for preferred rank

2 December 2017

title

A Phase II study of high dose tamoxifen in progressive, metastatic renal cell (English)

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058136

14 October 2022

A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606089

14 October 2022

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058136

14 October 2022

1 reference

M. Stahl

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606089

14 October 2022

H. Wilke

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606089

14 October 2022

H. J. Schmoll

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606089

14 October 2022

C. Schöber

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606089

14 October 2022

H. Diedrich

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606089

14 October 2022

J. Casper

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606089

14 October 2022

M. Freund

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606089

14 October 2022

H. Poliwoda

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606089

14 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1606089

14 October 2022

publication date

1 February 1992

1 reference

full work available at URL

2 December 2017

http://annonc.oxfordjournals.org/cgi/content/abstract/3/2/167

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1606089

https://api.elsevier.com/content/article/PII:S0923753419651653?httpAccept=text/xml

14 October 2022

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058136

https://api.elsevier.com/content/article/PII:S0923753419651653?httpAccept=text/plain

14 October 2022

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058136

http://academic.oup.com/annonc/article-pdf/3/2/167/531029/3-2-167.pdf

14 October 2022

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058136

14 October 2022

1 reference

2 December 2017

volume

3

1 reference

2 December 2017

issue

2

1 reference

2 December 2017

page(s)

167-168

1 reference

Reporting results of cancer treatment

2 December 2017

cites work

4

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058136

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

14 October 2022

5

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058136

The role of biological response modifiers in metastatic renal cell carcinoma

14 October 2022

7

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058136

Interferon in renal cell carcinoma. The UCLA experience.

14 October 2022

8

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058136

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

14 October 2022

9

1 reference

https://api.crossref.org/works/10.1093/OXFORDJOURNALS.ANNONC.A058136

14 October 2022

Identifiers

1 reference

2 December 2017

1 reference